**BMJ open**
accessible medical research

# Stratified assessment of the role of inhaled hypertonic saline in reducing cystic fibrosis pulmonary exacerbations: a retrospective analysis

Dayton Dmello, Ravi P Nayak, George M Matuschak

Division of Pulmonary, Critical Care & Sleep Medicine, Saint Louis University School of Medicine, St Louis, Missouri, USA

**Correspondence to**
Dayton Dmello;
ddmello@slu.edu

## ABSTRACT

**Objective:** Limited data exist concerning the role of inhaled hypertonic saline (HS) in decreasing pulmonary exacerbations in cystic fibrosis (CF), especially as more advanced stages of CF lung disease were excluded in prior studies. Herein, the authors retrospectively determined the efficacy of inhaled HS in reducing CF pulmonary exacerbations when stratified according to the severity of CF lung disease. Stratification was based on the framework of the Pulmonary Therapeutics Committee's published gradation of obstructive lung physiology in CF, that is, mild ($FEV_1 > 70\%$), moderate ($FEV_1$ 40−70%) and severe ($FEV_1 < 40\%$) lung disease, respectively.

**Design:** A retrospective review of the Port CF database over a 3-year period performed at an academic CF care centre.

**Results:** 340 pulmonary exacerbations were identified; inhaled HS was being used in 99 of these cases. Univariate analysis demonstrated a significant reduction in pulmonary exacerbations only in mild obstruction (OR=0.09, CI 0.01 to 0.81, p=0.012); however, multivariate logistic regression that adjusted for confounding variables showed a reduction in pulmonary exacerbations across the entire spectrum of obstructive lung disease when using inhaled HS, that is, mild obstructive CF lung disease (OR=0.17, CI 0.05 to 0.58, p=0.004), moderate obstructive CF lung disease (OR=0.39, CI 0.16 to 0.93, p=0.034), as well as severe obstructive CF lung disease (OR=0.02, CI 0.001 to 0.45, p=0.015). Moreover, inhaled HS appeared reasonably well tolerated across all stages of lung-disease severity, and was discontinued in only 7% of cases (n=4) with severe lung disease.

**Conclusion:** In this study, inhaled HS appeared to reduce pulmonary exacerbations in CF lung disease at all stages of obstruction. This underscores the importance of therapeutic inhaled HS in CF lung disease, regardless of the severity of lung obstruction.

## INTRODUCTION

Cystic fibrosis (CF) is characterised by decreased clearance of airway mucus that over time leads to progressive inflammatory loss of lung function consequent to infectious

## ARTICLE SUMMARY

### Article focus
- Prior studies have demonstrated that inhaled hypertonic saline (HS) improves the forced expiratory volume in 1 s ($FEV_1$) and the forced vital capacity (FVC) in patients with cystic fibrosis.
- Inhaled HS also decreases the frequency of pulmonary exacerbations in cystic fibrosis; this aspect has been less extensively studied, especially in more severe forms of disease.
- This study focuses on the role of inhaled HS in decreasing the frequency of pulmonary exacerbations in patients stratified according to the severity of CF lung disease.

### Key messages
- This study suggests that inhaled HS may be beneficial in reducing pulmonary exacerbations at all stages of CF lung disease severity, thus highlighting the importance of inhaled HS as a key component of the CF therapeutic armamentarium.
- The observed benefit of inhaled HS appeared in addition to that of established airway clearance strategies such as nebulised rhDNase therapy and mechanical airway clearance devices.
- This study found no indication of any excessive discontinuation of inhaled HS due to cough or bronchospasm in more severe forms of CF lung disease, suggesting that it is reasonably well tolerated even in such cases.

exacerbations.[1] In this context, the landmark trial of Elkins and colleagues[2] established that inhaled hypertonic 7% saline (HS) nebulised twice daily in CF lung disease improved the overall forced expiratory volume in 1 s ($FEV_1$) and the forced vital capacity (FVC) by 68 ml and 82 ml, respectively, although it did not appreciably alter the rate of decline of $FEV_1$. The effect of inhaled HS in decreasing the frequency of clinical exacerbations of CF lung disease was reported as a secondary outcome in this trial;

## ARTICLE SUMMARY

### Strengths and limitations of this study

- This study establishes the role of inhaled HS in reducing the number of pulmonary exacerbations at more advanced stages of CF lung disease severity, which is of special significance considering that the more severe forms of CF lung disease had been excluded in previous studies.
- Our study group had a significantly higher usage of nebulised rhDNase (100%) and other mechanical airway clearance therapies (97%) compared with previous studies, thus supporting the additional beneficial effect of inhaled HS.
- Our two study groups had differences in epidemiological characteristics, potentially introducing bias into the results. We have attempted to minimise for this by performing a logistic regression; however, we acknowledge the inherent limitations of such a retrospective study design.

a 56% relative reduction in exacerbations for the HS-treated group.[2] Prior to this report, other trials had likewise demonstrated the short-term benefit of HS,[3][4] but had not specifically addressed the effect of inhaled HS in decreasing pulmonary exacerbations in CF lung disease. We sought to better define the therapeutic role of inhaled HS in reducing the frequency of pulmonary exacerbations based on the severity of underlying CF lung disease; this is in accordance with the current stratified framework of evidence-based Cystic Fibrosis Pulmonary Guidelines.[5] The original abstract of this study was presented at the 2009 annual scientific meeting of the American College of Chest Physicians.[6]

## METHODS

A retrospective assessment of the Saint Louis University (SLU) institutional data within the Port CF database registry was performed. The SLU CF care centre is a combined adult and paediatric academic accredited CF centre. The Port CF registry captures both clinical and epidemiological data from all CF patient during each individual visit to the CF care centre, and is recorded as per an established nationwide protocol. Approval was obtained from the Institutional Review Board at SLU. We initially identified a cohort of CF patients who presented over a 3-year period beginning January 2006, corresponding to the publication of the Elkins study.[2] All episodes of pulmonary exacerbations necessitating either hospitalisation or treatment with home intravenous antibiotics were identified. Other recorded variables included utilisation of inhaled HS, airway-clearance methodologies, demographics, sputum culture results and spirometric indices. Groups were compared utilising $\chi^2$ and independent t testing for categorical and continuous variables, respectively. The severity of CF lung disease was further stratified into three groups based on the framework of the Pulmonary Therapeutics Committee's published gradation of obstructive lung physiology in CF,[5] that is, mild ($FEV_1$ >70% predicted), moderate ($FEV_1$ 40−70% predicted)

and severe ($FEV_1$ <40% predicted) lung disease, respectively. A univariate $\chi^2$ analysis was performed separately in all three subgroups to assess the effects of HS in reducing the frequency of pulmonary exacerbations; consequently, a p value of 0.016 was considered significant utilising a Bonferroni adjustment for multiple comparisons. Finally, a logistic regression was also performed in all subgroups to adjust for differences in subgroup characteristics such as age, gender, BMI, inhaled HS, sputum positivity for MRSA or *Pseudomonas*, as well as the spirometric $FEV_1$ and FVC. A statistical analysis was performed using SPSS V.17.

## RESULTS

Overall, 340 pulmonary exacerbations were identified from a cohort of 424 patients. The average age of the entire cohort was 31±11 years, and 55% were male. Inhaled HS was being used in 99/340 cases with exacerbations (29%). Fifty patients (12%), 183 patients (45%) and 170 patients (42%) of the cohort were categorised as having mild, moderate and severe CF lung disease, respectively; 21 patients were uncategorised secondary to unclear documentation of the $FEV_1$. Demographic and clinical variables are summarised in table 1. Using a univariate analysis, we found a significant reduction in pulmonary exacerbations in the subgroup of patients using HS with mild lung disease (OR=0.09, CI 0.01 to 0.81, p=0.012), whereas no reductions were found in the cohort of subjects with moderate (OR=1.33, CI 0.65 to 2.74, p=0.432) and severe lung disease (OR=5.62, CI 0.73 to 43.21, p=0.063). However, a subsequent multivariate analysis using logistic regression modelling demonstrated a reduction in pulmonary exacerbations when using HS at all stages of obstruction, that is, mild obstructive CF lung disease (OR=0.17, CI 0.05 to 0.58, p=0.004), moderate obstructive CF lung disease (OR=0.39, CI 0.16 to 0.93, p=0.034), as well as severe obstructive CF lung disease (OR=0.02, CI 0.001 to 0.45, p=0.015). These findings are summarised in tables 2, 3, with individual regression tables in the supplementary appendix. Additionally, inhaled HS was discontinued in only four cases (7%) with severe lung disease.

## DISCUSSION

Exacerbations of CF lung disease account for appreciable morbidity and burden of this disease, which collectively greatly decrease physical functioning and psychosocial quality of life.[7] Pulmonary exacerbations in particular significantly contribute to the overall cost of CF care, accounting for up to 47% of overall costs in one study.[8] Accordingly, measures to decrease pulmonary exacerbations are important. Inhaled HS decreases the viscosity of pulmonary secretions and thereby improves the rheological properties of mucus secondary to hydration of the airway surface.[9] In addition, HS osmotically induces a sustained increase in the airway surface liquid volume depth, possibly allowing the cilia

**Table 1** Baseline epidemiological characteristics between hypertonic-saline-treated and non-treated groups

|  | Hypertonic saline (n=121) | No hypertonic saline (n=303) | p Value |
|---|---|---|---|
| Age, mean±SD | 33±10 | 31±12 | 0.13 |
| Male gender, n (%) | 37 (31%) | 196 (65%) | <0.001 |
| Body mass index, mean±SD | 20.8±0.7 | 21.9±5.7 | 0.001 |
| Forced expiratory volume in 1 s (% predicted), mean±SD | 50±12 | 46±23 | 0.016 |
| Forced vital capacity (% predicted), mean±SD | 73±9 | 57±24 | <0.001 |
| Use of recombinant human DNase, n (%) | 121 (100%) | 303 (100%) | NA |
| Sputum positivity for *Pseudomonas aeruginosa*, n (%) | 60 (50%) | 211 (70%) | <0.001 |
| Sputum positivity for methicillin-resistant *Staphylococcus aureus*, n (%) | 60 (50%) | 97 (32%) | 0.001 |
| Airway-clearance device (chest vest or flutter valve), n (%) | 80 (93%) | 143 (97%) | |
| Hospitalisation/home intravenous antibiotics, n (%) | 41 (52%)/41 (48%) | 88 (60%)/60 (40%) | |

to beat freely by recoupling the mucociliary mechanism.[10] Inhaled HS for CF lung disease is currently assigned a Grade II recommendation in the Cystic Fibrosis Pulmonary Guidelines published in 2007,[5] based on evidence from the above-cited trials.[2–4] Notably, in the trial reporting the efficacy of HS in reducing clinical exacerbations,[2] patients with severe CF lung disease (as classified by $FEV_1$ <40% predicted) were excluded; moreover, only approximately one-third of the included participants were using nebulised rhDNase.

Here, we have assessed the effects of inhaled HS in reducing the number of pulmonary exacerbations across varying levels of lung disease severity, especially considering that more severe forms of CF lung disease had been previously excluded.[2] Our study suggests that inhaled HS is beneficial in reducing exacerbations across all stages of CF lung disease using multivariate analyses, even though the univariate analysis only showed benefit in mild CF lung disease. These findings underscore the potential therapeutic benefit of initiating inhaled HS at any stage in the disease continuum. Our study group had a significantly higher usage of nebulised rhDNase (100%) and other mechanical airway clearance therapies (97%) compared with previous studies.[2] Hence, we postulate that there may be an additional benefit of inhaled HS in patients who are already on established airway-clearance strategies. We also found no indication of any excessive discontinuation of inhaled HS due to cough or bronchospasm in more severe forms of CF lung

disease, suggesting that it is reasonably well tolerated even in such cases.

Even so, the methodological limitations of our study must be acknowledged, principally its retrospective nature and lack of randomisation. Mild exacerbations could possibly go unreported; moreover, there was no uniform protocol in place to assess compliance with therapy. Furthermore, the two study groups had differences in epidemiological characteristics, for example, the lower proportion of sputum *Pseudomonas* positivity in HS users, thereby potentially lending bias to our interpretation. In this context, regression analyses in an attempt to adjust for these variable clinical and epidemiological characteristics were performed. However, ultimately, prospective randomised controlled studies with larger numbers of included participants are warranted to better assess the benefit of inhaled HS at varying stages of CF lung-disease severity.

## CONCLUSION
Our study demonstrated that pulmonary exacerbations appear to be reduced in patients with CF lung disease of any severity during active use of inhaled HS. The beneficial effect of HS was additive to other airway-clearance measures such as nebulised rhDNase and mechanical clearance strategies. Moreover, inhaled HS appeared reasonably well tolerated. Recently, the effectiveness of alternative therapies such as nebulised mannitol for mucociliary clearance has been reported.[11] Until these newer strategies are better established, we support the

**Table 2** ORs using inhaled hypertonic saline (n=99) for pulmonary exacerbations (n=340) using a univariate analysis

| Lung-disease severity | OR | CIs Lower | CIs Higher | p Value |
|---|---|---|---|---|
| Mild (n=50) | 0.09 | 0.01 | 0.812 | **0.012** |
| Moderate (n=183) | 1.33 | 0.65 | 2.74 | 0.432 |
| Severe (n=170) | 5.62 | 0.73 | 43.21 | 0.063 |

Numbers in bold indicate statistical significance.

**Table 3** ORs using inhaled hypertonic saline (n=99) for pulmonary exacerbations (n=340) using a multivariate analysis

| Lung-disease severity | OR | CIs Lower | CIs Higher | p Value |
|---|---|---|---|---|
| Mild (n=50) | 0.17 | 0.05 | 0.58 | **0.004** |
| Moderate (n=183) | 0.39 | 0.16 | 0.93 | **0.034** |
| Severe (n=170) | 0.02 | 0.001 | 0.452 | **0.015** |

use of inhaled HS in CF lung disease, in the context of reducing pulmonary exacerbations. This is especially so given the potential to improve lung function, quality of life, CF-related costs and possibly mortality.[1 7 8 12 13]

## REFERENCES

1. Flume PA, Mogayzel PJ Jr, Robinson KA, *et al*; Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. *Am J Respir Crit Care Med* 2009;180:802—8.
2. Elkins MR, Robinson M, Rose BR, *et al*; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. *N Engl J Med* 2006;354:229—40.
3. Eng PA, Morton J, Douglass JA, *et al*. Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. *Pediatr Pulmonol* 1996;21:77—83.
4. Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis (Review). *Cochrane Database Syst Rev* 2009;(2):CD001506.
5. Flume PA, O'Sullivan BP, Robinson KA, *et al*. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. *Am J Respir Crit Care Med* 2007;176:957—69.
6. Dmello D, Oliver D, Nayak RP. Efficacy of inhaled hypertonic saline in reducing exacerbations of cystic fibrosis lung disease [abstract]. *Chest* 2009;136:9S—10S.
7. Britto MT, Kotagal UR, Homung RW, *et al*. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. *Chest* 2002;121:64—72.
8. Lieu TA, Ray T, Farmer G, *et al*. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. *Pediatrics* 1999;103:e72.
9. Tarran R, Donaldson S, Boucher RC. Rationale for hypertonic saline therapy for cystic fibrosis lung disease. *Semin Respir Crit Care Med* 2007;28:295—302.
10. Elkins MR, Bye PT. Inhaled hypertonic saline as a therapy for cystic fibrosis. *Curr Opin Pulm Med* 2006;12:445—52.
11. Minasian CC, Wallis C, Metcalfe C, *et al*. Comparison of inhaled mannitol, daily rhDNase, and a combination of both in children with cystic fibrosis: a randomized trial. *Thorax*. Published Online First: 8 December 2009. doi:10.1136/thx.2009.116970.
12. Marshall BC. Pulmonary exacerbations in cystic fibrosis. it's time to be explicit! *Am J Respir Crit Care Med* 2004;169:781—2.
13. Liou TG, Adler FR, FitzSimmons SC, *et al*. Predictive 5-year survivorship model of cystic fibrosis. *Am J Epidemiol* 2001;153:345—52.

**Supplemental Table A. Logistic Regression modeling for pulmonary exacerbations in mild**

**CF lung disease using inhaled HS**

| | Wald | Odds Ratio (OR) | Confidence Intervals for OR | | $p$ value |
|---|---|---|---|---|---|
| | | | Lower | Upper | |
| Age | 2.898 | 1.044 | 0.993 | 1.097 | 0.089 |
| FEV$_1$ [a] | 2.001 | 0.944 | 0.872 | 1.022 | 0.157 |
| FVC [b] | 1.197 | 1.056 | 0.958 | 1.163 | 0.274 |
| BMI [c] | 2.105 | 1.096 | 0.968 | 1.242 | 0.147 |
| Gender | 0.362 | 0.731 | 0.263 | 2.028 | 0.547 |
| Inhaled HS [d] use | 8.139 | 0.173 | 0.052 | 0.577 | 0.004 |
| Sputum positivity for Pseudomonas | 4.569 | 3.305 | 1.104 | 9.892 | 0.033 |
| Sputum positivity for MRSA [e] | 2.312 | 2.748 | 0.747 | 10.113 | 0.128 |

[a] FEV1 = Forced Expiratory Volume in One Second

[b] FVC = Forced Vital Capacity

[c] BMI = Body Mass Index

[d] HS = Hypertonic Saline

[e] MRSA = Methicillin Resistant Staphylococcus Aureus

**Supplemental Table B. Logistic Regression modeling for pulmonary exacerbations in moderate CF lung disease using inhaled HS**

| | Wald | Odds Ratio (OR) | Confidence Intervals for OR | | $p$ value |
|---|---|---|---|---|---|
| | | | Lower | Upper | |
| Age | 0.378 | 1.012 | 0.974 | 1.052 | 0.538 |
| FEV$_1$ [a] | 23.369 | 0.892 | 0.851 | 0.934 | < 0.001 |
| FVC [b] | 5.709 | 1.073 | 1.013 | 1.136 | 0.017 |
| BMI [c] | 1.644 | 1.088 | 0.956 | 1.237 | 0.2 |
| Gender | 4.385 | 0.41 | 0.178 | 0.945 | 0.036 |
| Inhaled HS [d] use | 4.508 | 0.39 | 0.164 | 0.93 | 0.034 |
| Sputum positivity for Pseudomonas | 1.663 | 1.966 | 0.704 | 5.495 | 0.197 |
| Sputum positivity for MRSA [e] | 1.027 | 1.86 | 0.56 | 6.176 | 0.311 |

[a] FEV1 = Forced Expiratory Volume in One Second

[b] FVC = Forced Vital Capacity

[c] BMI = Body Mass Index

[d] HS = Hypertonic Saline

[e] MRSA = Methicillin Resistant Staphylococcus Aureus

**Supplemental Table C. Logistic Regression modeling for pulmonary exacerbations in severe CF lung disease using inhaled HS**

| | Wald | Odds Ratio (OR) | Confidence Intervals for OR | | *p* value |
|---|---|---|---|---|---|
| | | | Lower | Upper | |
| Age | 0.098 | 0.988 | 0.916 | 1.066 | 0.754 |
| FEV$_1$ [a] | 0.608 | 0.769 | 0.397 | 1.489 | 0.436 |
| FVC [b] | 0.692 | 1.192 | 0.788 | 1.804 | 0.406 |
| BMI [c] | 0.339 | 0.877 | 0.564 | 1.364 | 0.56 |
| Gender | 2.724 | 5.756 | 0.72 | 46.007 | 0.099 |
| Inhaled HS [d] use | 5.911 | 0.017 | 0.001 | 0.452 | 0.015 |
| Sputum positivity for Pseudomonas | 4.620 | 53.471 | 1.42 | 2013.278 | 0.032 |
| Sputum positivity for MRSA [e] | 5.081 | 0.051 | 0.004 | 0.677 | 0.024 |

[a] FEV1 = Forced Expiratory Volume in One Second

[b] FVC = Forced Vital Capacity

[c] BMI = Body Mass Index

[d] HS = Hypertonic Saline

[e] MRSA = Methicillin Resistant Staphylococcus Aureus

# STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *case-control studies*

| Section/Topic | Item # | Recommendation | Reported on page # |
|---|---|---|---|
| **Title and abstract** | 1 | (*a*) Indicate the study's design with a commonly used term in the title or the abstract | 1 |
| | | (*b*) Provide in the abstract an informative and balanced summary of what was done and what was found | 2 |
| **Introduction** | | | |
| Background/rationale | 2 | Explain the scientific background and rationale for the investigation being reported | 5 |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | 5 |
| **Methods** | | | |
| Study design | 4 | Present key elements of study design early in the paper | 5,6 |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | 5,6 |
| Participants | 6 | (*a*) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls | 5,6 |
| | | (*b*) For matched studies, give matching criteria and the number of controls per case | |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | 6 |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | 5,6 |
| Bias | 9 | Describe any efforts to address potential sources of bias | 6 |
| Study size | 10 | Explain how the study size was arrived at | 5 |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | |
| Statistical methods | 12 | (*a*) Describe all statistical methods, including those used to control for confounding | 5 |
| | | (*b*) Describe any methods used to examine subgroups and interactions | 5 |
| | | (*c*) Explain how missing data were addressed | |
| | | (*d*) If applicable, explain how matching of cases and controls was addressed | |
| | | (*e*) Describe any sensitivity analyses | |
| **Results** | | | |

| | | | |
|---|---|---|---|
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | 6,7 |
| | | (b) Give reasons for non-participation at each stage | |
| | | (c) Consider use of a flow diagram | |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | 8 |
| | | (b) Indicate number of participants with missing data for each variable of interest | |
| Outcome data | 15* | Report numbers in each exposure category, or summary measures of exposure | 6,7,9 |
| Main results | 16 | (*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | |
| | | (*b*) Report category boundaries when continuous variables were categorized | |
| | | (*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | |
| **Discussion** | | | |
| Key results | 18 | Summarise key results with reference to study objectives | 6,7 |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | 11 |
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | 11 |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | |
| **Other information** | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | 11 |

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.